ALNY vs. RDY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and RDY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization of 43.28 billion USD is substantially larger than RDY’s 12.55 billion USD, indicating a significant difference in their market valuations.
RDY carries a higher beta at 0.39, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
RDY is an American Depositary Receipt (ADR), allowing U.S. investors direct exposure to its non-U.S. operations. ALNY, on the other hand, is a domestic entity.
| Symbol | ALNY | RDY |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Dr. Reddy's Laboratories Limited |
| Country | US | IN |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| CEO | Yvonne L. Greenstreet | Erez Israeli |
| Price | 331.91 USD | 15.08 USD |
| Market Cap | 43.28 billion USD | 12.55 billion USD |
| Beta | 0.21 | 0.39 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | April 11, 2001 |
| ADR | No | Yes |
Historical Performance
This chart compares the performance of ALNY and RDY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
RDY
18.08%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 51.32%
- Q3
- 9.89%
- Median
- -3.37%
- Q1
- -20.99%
- Min
- -36.07%
In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, RDY’s Return on Equity of 18.08% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
RDY
13.27%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 22.54%
- Q3
- 8.45%
- Median
- 1.42%
- Q1
- -9.01%
- Min
- -28.41%
In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, RDY’s Return on Invested Capital of 13.27% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
RDY
17.37%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.33%
- Q3
- 11.92%
- Median
- -0.45%
- Q1
- -13.07%
- Min
- -34.27%
A Net Profit Margin of 17.37% places RDY in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
RDY
21.95%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 46.91%
- Q3
- 19.02%
- Median
- 6.23%
- Q1
- -11.23%
- Min
- -51.89%
An Operating Profit Margin of 21.95% places RDY in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALNY | RDY |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 18.08% |
| Return on Assets (TTM) | -6.40% | 11.47% |
| Return on Invested Capital (TTM) | -2.79% | 13.27% |
| Net Profit Margin (TTM) | -11.49% | 17.37% |
| Operating Profit Margin (TTM) | -4.91% | 21.95% |
| Gross Profit Margin (TTM) | 86.01% | 57.17% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RDY
1.92
Drug Manufacturers - Specialty & Generic Industry
- Max
- 5.74
- Q3
- 3.37
- Median
- 2.64
- Q1
- 1.73
- Min
- 0.88
RDY’s Current Ratio of 1.92 aligns with the median group of the Drug Manufacturers - Specialty & Generic industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
RDY
0.14
Drug Manufacturers - Specialty & Generic Industry
- Max
- 1.45
- Q3
- 1.06
- Median
- 0.62
- Q1
- 0.13
- Min
- 0.00
RDY’s Debt-to-Equity Ratio of 0.14 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
RDY
32.89
Drug Manufacturers - Specialty & Generic Industry
- Max
- 10.17
- Q3
- 3.39
- Median
- 0.85
- Q1
- -2.63
- Min
- -5.84
With an Interest Coverage Ratio of 32.89, RDY demonstrates a superior capacity to service its debt, placing it well above the typical range for the Drug Manufacturers - Specialty & Generic industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | ALNY | RDY |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.92 |
| Quick Ratio (TTM) | 2.98 | 1.37 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.14 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.09 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 0.35 |
| Interest Coverage Ratio (TTM) | -0.79 | 32.89 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and RDY. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RDY
0.61%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 9.29%
- Q3
- 0.31%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.61%, RDY offers a more attractive income stream than most of its peers in the Drug Manufacturers - Specialty & Generic industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RDY
11.78%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 125.42%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RDY’s Dividend Payout Ratio of 11.78% is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ALNY | RDY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.61% |
| Dividend Payout Ratio (TTM) | 0.00% | 11.78% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
RDY
19.29
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.89
- Q3
- 28.12
- Median
- 23.94
- Q1
- 18.79
- Min
- 7.76
RDY’s P/E Ratio of 19.29 is within the middle range for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
RDY
-5.44
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.19
- Q3
- 2.94
- Median
- 1.47
- Q1
- 0.35
- Min
- 0.00
RDY has a negative Forward PEG Ratio of -5.44. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RDY
3.35
Drug Manufacturers - Specialty & Generic Industry
- Max
- 7.49
- Q3
- 4.45
- Median
- 2.12
- Q1
- 1.21
- Min
- 0.25
RDY’s P/S Ratio of 3.35 aligns with the market consensus for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
RDY
3.27
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.93
- Q3
- 3.95
- Median
- 2.14
- Q1
- 1.30
- Min
- 0.13
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.
Valuation at a Glance
| Symbol | ALNY | RDY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 19.29 |
| Forward PEG Ratio (TTM) | -43.29 | -5.44 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 3.35 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | 3.27 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 71.17 |
| EV-to-EBITDA (TTM) | -285.32 | 12.30 |
| EV-to-Sales (TTM) | 18.55 | 3.45 |